Skip to main content
Therapeutic Advances in Medical Oncology logoLink to Therapeutic Advances in Medical Oncology
. 2021 Jul 16;13:17588359211034059. doi: 10.1177/17588359211034059

Corrigendum to “Clinical impact of the tumor immune microenvironment in completely resected stage IIIA(N2) non-small cell lung cancer based on an immunoscore approach”

PMCID: PMC8287639  PMID: 34349844

Feng W, Li Y, Shen L, et al. Clinical impact of the tumor immune microenvironment in completely resected stage IIIA(N2) non-small cell lung cancer based on an immunoscore approach. Ther Adv Med Oncol 2021; 13: 1-14. DOI: 10.1177/1758835920984975

The authors of the above-mentioned paper have been informed post-publication that the term ‘immunoscore’ used in the paper is a trademarked term. The term has therefore been replaced in the title and six times throughout the text with the generic term ‘immunological score (IS)’, and the published version of the article has been changed to reflect this. The authors apologize for this error.


Articles from Therapeutic Advances in Medical Oncology are provided here courtesy of SAGE Publications

RESOURCES